Compare TOPS & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOPS | SXTP |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 1.8M |
| IPO Year | 2004 | 2023 |
| Metric | TOPS | SXTP |
|---|---|---|
| Price | $2.15 | $0.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.70 |
| AVG Volume (30 Days) | 303.3K | ★ 307.4K |
| Earning Date | 09-16-2026 | 11-16-2026 |
| Dividend Yield | ★ 35.44% | N/A |
| EPS Growth | N/A | ★ 36.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,005,471.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.00 |
| P/E Ratio | $2.14 | ★ N/A |
| Revenue Growth | N/A | ★ 65.49 |
| 52 Week Low | $0.26 | $0.34 |
| 52 Week High | $7.40 | $8.62 |
| Indicator | TOPS | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 63.71 | 32.36 |
| Support Level | $0.59 | N/A |
| Resistance Level | $2.31 | $1.01 |
| Average True Range (ATR) | 0.31 | 0.08 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 53.44 | 7.13 |
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco-tanker vessels, focusing on the transportation of crude oil, petroleum products (both clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements. The company operates in two reportable segments: (i) the tanker segment and (ii) the megayacht segment.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.